| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7265117 | SANDOZ | Topical brimonidine tartrate formulations that lack chlorine dioxide |
Aug, 2025
(1 year, 3 months from now) | |
Qoliana is owned by Sandoz.
Qoliana contains Brimonidine Tartrate.
Qoliana has a total of 1 drug patent out of which 0 drug patents have expired.
Qoliana was authorised for market use on 22 May, 2006.
Qoliana is available in solution/drops;ophthalmic dosage forms.
The generics of Qoliana are possible to be released after 19 August, 2025.
Drugs and Companies using
BRIMONIDINE TARTRATE ingredient
Market Authorisation Date:
22 May, 2006Treatment:
NADosage:
SOLUTION/DROPS;OPHTHALMIC
More Information on Dosage
QOLIANA family patents
